Business
-
According to Viatris, the US District Court for the Northern District of West Virginia has determined that US Patent No. 10,166,247, which covers AstraZeneca’s Symbicort budesonide / formoterol MDI, is invalid. In March 2021, the same court upheld… Read more . . .
-
Tyrvaya varenicline nasal spray maker Oyster Point Pharma announced that its board of directors has approved the company’s plans to be acquired by Viatris for $11 per share at closing plus up to $2 per… Read more . . .
-
TFF Pharmaceuticals announced that it has been working with Aptar Pharma on a project to develop dry powder vaccines based on TFF’s thin film freezing particle manufacturing platform and Aptar Pharma’s Unidose (UDS) nasal powder… Read more . . .
-
Birmingham Biotech has announced the launch of NoriZite carageenan/gellan gum nasal spray for the prevention of viral infections in the UK. The formulation, which is designed to physically block viruses in the nasal cavity, was developed… Read more . . .
-
According to Liquidia, the US Patent and Trademark Office’s Precedential Opinion Panel (POP) will not review a July 2022 Patent Trial and Appeals Board (PTAB) decision which determined that none of the claims in US Patent No. 10,716,793, which covers… Read more . . .
-
Lupin Limited announced that it will pay Sunovion $75 million for the rights to Brovana arformoterol inhalation solution and Xopenex HFA levalbuterol MDI. Brovana has been approved in the US for the treatment of COPD… Read more . . .
-
According to CDMO GenScript ProBio, the company has signed an agreement with Thai company Hibiocy for manufacturing of Covitrap, an intranasal antibody cocktail for the prevention of COVID-19. GenScript said that the deal includes both… Read more . . .
-
Transpire Bio, which previously announced deals with Recipharm for development of four inhaled products, announced a new deal with INTO (Inhalation Together) for development of three additional inhaled products: TRB-5, TRB-6 and TRB-7. INTO is… Read more . . .
-
Odyssey Health has announced the creation of a subsidiary called Odyssey Neuropharma that will develop intranasal drugs for the treatment of neurological disorders, including PRV-002 intranasal synthetic neurosteroid for the treatment of concussion. In addition to… Read more . . .
-
Blue Water Vaccines said that it intends to develop its BWV-201 intranasal Streptococcus pneumoniae vaccine candidate for the prevention of non-invasive pneumococcal pneumonia. The company is already developing the live attenuated intranasal vaccine, which it licensed… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan